Thalamic Nuclei Volumes in Multiple Sclerosis

NCT05002764 | Unknown

• 1 other identifier: CHUBX 2021/33
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

The thalamus is composed of several nuclei interlocked in a complex anatomy. In multiple sclerosis (MS), the thalamus can be altered due to disconnection by white matter lesions and due to direct damages that could be partly mediated by CSF. Due to such pathophysiology and complex anatomy, some nuclei could be more vulnerable to multiple sclerosis than others. We will test this hypothesis by using a new algorithm to automatically segment several nuclei that we will be applied to the French national MS database

Conditions

Multiple Sclerosis

Keywords

Multiple sclerosis; Thalamus; Nuclei; Atrophy

Outcome Measures

Primary Outcomes (1)

• Volume of thalamic nuclei

  Volume of individual thalamic nuclei according to disease duration.

  At inclusion in the cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with Multiple Sclerosis and at least one MRI that includes 3D T1 and FLAIR at 1.5T or 3T.

You may qualify if:

• Patient older than 18 years old.
• With Multiple Sclerosis according to Mc Donald 2017 criteria or with clinically isolated syndrome and included with OFSEP cohort.
• Phenotype known (RR, SP, PP or CIS).
• Date of diagnosis known.
• With at least one MRI that includes 3D T1 and FLAIR at 1.5T or 3T.

You may not qualify if:

• Stroke
• Other causes of dementia not caused by Multiple Sclerosis (Alzheimer's disease, Parkinsonian syndromes…)

Sponsors & Collaborators

• University Hospital, Bordeaux: lead
• Institut National de la Santé Et de la Recherche Médicale, France: collaborator

Study Sites (1)

CHU Bordeaux

Bordeaux, 33 076, France

RECRUITING

MeSH Terms

Conditions

Multiple Sclerosis; Atrophy

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Thomas Tourdias, Pr

CONTACT

05 56 79 56 04; thomas.tourdias@chu-bordeaux.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 24 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 4, 2021
• First Posted: August 12, 2021
• Study Start: July 1, 2021
• Primary Completion: July 1, 2023
• Study Completion: July 1, 2023
• Last Updated: August 12, 2021

Record last verified: 2021-08

Locations

FR (1)